slide1 l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
ASCEND-HF A cute S tudy of C linical E ffectiveness of N esiritide in Subjects with D ecompensated H eart F ailur PowerPoint Presentation
Download Presentation
ASCEND-HF A cute S tudy of C linical E ffectiveness of N esiritide in Subjects with D ecompensated H eart F ailur

Loading in 2 Seconds...

play fullscreen
1 / 10

ASCEND-HF A cute S tudy of C linical E ffectiveness of N esiritide in Subjects with D ecompensated H eart F ailur - PowerPoint PPT Presentation


  • 334 Views
  • Uploaded on

ASCEND-HF A cute S tudy of C linical E ffectiveness of N esiritide in Subjects with D ecompensated H eart F ailure. Duke Heart Failure Research Pager: 970-0736. Purpose.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'ASCEND-HF A cute S tudy of C linical E ffectiveness of N esiritide in Subjects with D ecompensated H eart F ailur' - liam


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

ASCEND-HFAcute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure

Duke Heart Failure Research

Pager: 970-0736

purpose
Purpose
  • Double blinded placebo-controlled study to evaluate efficacy and safety of Nesiritide (Natrecor) in addition to standard care vs. placebo with standard care in patients with acute decompensated heart failure.
    • Double blinded study meaning subjects, MD, and research team are unaware of what treatment is being received.
slide3
Nesiritide(Natrecor) – A medication used to treat acute decompensted HF. It is a form of human BNP that promotes vasodilation, natriuresis, and diuresis.
inclusion criteria
Dyspnea at rest

Pulmonary congestion

Signs/symptoms within 24 hrs of admission

Inclusion Criteria
interventions
Interventions
  • USE OF OPEN LABEL NESIRITIDE IS NOT ALLOWED AT ANY TIME!!
slide6
See “Protocol Instructions” and follow titration directions.This information is kept in patient’s chart box.
  • Side effects of Nesiritide (see Adverse Reactions List): http://www.clinicalpharmacology-ip.com/Forms/Monograph/monograph.aspx?cpnum=2134&sec=monadve
nursing roles
Nursing Roles
  • Nesiritide infusion of 0.010 mcg/kg/min with or without 2mcg/kg bolus vs. placebo
  • Change bag every 24 hrs.
  • Monitor VS q 5min. x4, q 30min. x2, and then q hr. x4
nursing roles8
Nursing Roles
  • Ask subjects to fill out questionnaires* and Visual Analog Scales (VAS)* at 6 and 24 hrs
    • QUESTIONNAIRES and VAS INCLUDE:
      • Dyspnea self assessments
      • Health status/well-being, mobility, self-care, pain, depression, activities

*Found in patient’s chart box.

outcomes
Outcomes
  • Why is this study being done?
    • Does Nesiritide decrease re-hospitalization or death in 30 days?
    • Does Nesiritide decrease symptoms of dyspnea at 6 and 24 hrs after drug initiated?
outcomes10
Outcomes
  • Measure overall well-being at 6 and 24 hrs
  • Measure # of days alive and # of days outside hospital from randomization to day 30
  • Measure cardiovascular re-hospitalization and mortality from randomization to day 30